Q-omics provides the consensus-scored SLC25A53P1 profile across patient tissues and cancer cell-line models. SLC25A53P1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SLC25A53P1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, SLC25A53P1 RNA expression shows 17,084 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight UCS, KIRC, and LIHC as cancer lineages where SLC25A53P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC25A53P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC25A53P1 survival associations across molecular data types. SLC25A53P1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC25A53P1 RNA expression–survival associations across cancer types. High SLC25A53P1 expression shows unfavorable associations in ACC, KIRP and STAD, but favorable associations in UCS, BRCA and LGG. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for SLC25A53P1 RNA expression.
This table summarizes SLC25A53P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC25A53P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC25A53P1 shows lower tumor expression in PRAD and higher tumor expression in KIRC, HNSC, KIRP, LUSC and BRCA. The KIRC box plot shows higher SLC25A53P1 RNA expression in tumor versus normal tissue (log2 FC = +0.076, t-test p < 0.001).
This table shows molecular features associated with SLC25A53P1 in patient tissues and cancer cell lines. In patient samples, SLC25A53P1 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
